EGFR and non-small cell lung carcinoma: Previously published meta-analyses had been conducted to explore the optimal first-line treatment for NSCLC harboring EGFR mutations and suggested gefitinib plus pemetrexed-based chemotherapy as one of the most effective strategies (the other one was osimertinib) [11, 12].